

FOR IMMEDIATE RELEASE

FIRST COMMERCIAL IMPLANT OF THE GORE[®] EXCLUDER[®] CONFORMABLE AAA ENDOPROSTHESIS WITH ACTIVE CONTROL SYSTEM IN CANADA

Bringing physicians a new degree of control and conformability

FLAGSTAFF, Ariz. (January 10, 2025) — W. L. Gore & Associates Medical Products (Gore) today announced the first commercial use of the GORE[®] EXCLUDER[®] Conformable AAA Endoprosthesis with ACTIVE CONTROL System in Canada.

The news coincides with Health Canada approval of the device for the treatment of abdominal aortic aneurysm (AAA) patients with aortic landing zones as short as 10 mm and neck angulation up to 90°.

Combining exceptional conformability with a delivery system fine-tuned for precision, the device offers physicians a new degree of control and a novel solution for highly angulated aortic necks.

"With the conformability of its nested stent design, angulation control and two-stage deployment, the GORE[®] EXCLUDER[®] Conformable AAA Device gives us the only option for endovascular repair of difficult angulated anatomy," remarked Kevin Lee, M.D., who used the device commercially for the first time.

"We can reconstrain. We can reposition. And we can refine angulation," he continued. "That means more control, more precision and more opportunities to achieve optimal seal." "We can reconstrain. We can reposition. And we can refine angulation," he continued. "That means more control, more precision and more opportunities to achieve optimal seal."

Kevin Lee, M.D. British Columbia, Canada

Media contact

Jessica Moran Goremedicalmedia@wlgore.com "Today was a major milestone for the tools and techniques at our disposal, and it built on the performance we've come to rely on over the years using the GORE[®] EXCLUDER[®] Device family."

"That really is a rare recipe for confidence with a new device," he concluded.

For Gore Medical Global Aortic Business Leader, Willy Davison, today's announcement "signals our continuing, core commitment to extend the global reach of our endovascular treatments."

"Progress doesn't happen overnight," Davison continued. "It takes years of work from countless contributors whose ideas and energy infuse the very fabric of our products. This device and delivery system are the culmination of decades of deep collaboration with physicians aimed at understanding and overcoming treatment challenges in aneurysmal disease."

"We're delighted to deliver this device for physicians in Canada," Davison added, "and, above all, for the patients in their care."

Medical Products

Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 55 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. For more information, visit goremedical.com

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments—from outer space to the world's highest peaks to the inner workings of the human body. With approximately 13,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of \$5 billion. gore.com

#

For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable *Instructions for Use* (IFU).

Products listed may not be available in all markets. GORE, *Together, improving life*, ACTIVE CONTROL, EXCLUDER and designs are trademarks of W. L. Gore & Associates. 24AR1124-EN01 JANUARY 2025